Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01732211 · ClinicalTrials.gov registry record · Phase 2
A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT01732211 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 1 participants.
The verdict
NCT01732211, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The study proposes to evaluate the safety, tolerability, and efficacy of PD 0360324 in subjects with chronic pulmonary sarcoidosis inadequately treated with standard of care therapies.
Interventions
- BIOLOGICAL PD 0360324
- OTHER Normal Saline for injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2013-03-15 |
| Est. Completion | 2013-09-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01732211
The ClinicalTrials.gov registry entry for NCT01732211 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PD 0360324 is the first listed.
NCT01732211 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01732211 about?
NCT01732211 is a clinical study titled "A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis". The study proposes to evaluate the safety, tolerability, and efficacy of PD 0360324 in subjects with chronic pulmonary sarcoidosis inadequately treated with standard of care therapies.
What is the current status of trial NCT01732211?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2013-03-15. Estimated completion is 2013-09-23.
What interventions are being tested in trial NCT01732211?
The interventions under investigation include: PD 0360324 (BIOLOGICAL), Normal Saline for injection (OTHER).
Who is sponsoring clinical trial NCT01732211?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.